It has been a while since I've written on Globus Medical (NYSE:GMED). I wasn't thrilled with the valuation back in February of 2014, but I'm surprised the shares are down over that time given reasonable progress with the business. I'm also surprised that the shares are trading at the valuation that they are - 2016 may not be shaping up as an exciting year in terms of revenue growth, and there are risks with the expansions into robotics and trauma, but the shares look undervalued for a company set to generate high-single-digit revenue growth with strong operating margins, good cash flow, and double-digit returns on invested capital.
Read the full article here:
Globus Medical Looks Like An Undervalued Innovator